Merck Gets CHMP Positive Opinion for Vaxneuvance Vaccine
October 15 2021 - 8:28AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Friday said the European Medicines Agency's
Committee for Medicinal Products for Human Use recommended approval
of its Vaxneuvance 15-valent pneumococcal vaccine in adults.
The Kenilworth, N.J., drugmaker said the recommendation covers
Vaxneuvance for active immunization for the prevention of invasive
disease and pneumonia caused by Streptococcus pneumoniae in
individuals 18 years of age and older.
The European Commission, which generally follows the CHMP's
advice, will now review the recommendations, with decisions
expected by the end of the year.
The U.S. Food and Drug Administration earlier this year approved
Vaxneuvance for adults.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 15, 2021 08:13 ET (12:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024